Biopsy core length in white versus African descendant prostate cancer patients

References

• Cancer health disparities. National Cancer Institute website. https://www.cancer.gov/about-nci/organization/crchd/cancer-health-disparities-fact-sheet#q9. 2017.
   Google Scholar
• Sundi D, Ross AE, Humphreys EB, et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? JCO. 2013;31(24):2991–2997.
   PubMed Web of Science ®Google Scholar
• Maurice MJ, Sundi D, Schaeffer EM, et al. Risk of pathological upgrading and up staging among men with low risk prostate cancer varies by race: results from the national cancer database. J Urol. 2017;197(3 Part 1):627–631.
   PubMed Web of Science ®Google Scholar
• https://www.auanet.org/guidelines/prostate-cancer-early-detection-(2013-reviewed-for-currency-2018).
   Google Scholar
• https://uroweb.org/guidelines/prostatecancer.
   Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
   PubMed Web of Science ®Google Scholar
• Ross R, Bernstein L, Judd H, et al. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986;76:45–48.
   PubMed Web of Science ®Google Scholar
• Jalloh M, Myers F, Cowan JE, et al. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. Eur Urol. 2015;67(3):451–457.
   PubMed Web of Science ®Google Scholar
• Moses KA, Orom H, Brasel A, et al. Racial/ethnic diferences in the relative risk of receipt of specific treatment among men with prostate câncer. Urol Oncol. 2016;34(9):415.e7–12.
   Web of Science ®Google Scholar
• Van der Kwast T, Bubendorf L, Mazerolles C, et al. Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European randomized study of screening for prostate cancer (ERSPC). Virchows Arch. 2013;463(3):367–377.
   PubMed Web of Science ®Google Scholar
• Berney DM, Algaba F, Camparo F, et.al. Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Arch. 2014;464(5):583–587.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice guidelines in oncology. www.nccn.org/professionals/physician_gls/f_guidelines.asp. 2017.
   Google Scholar
• Reis LO, Reinato JAS, Silva DC, et al. The impact of core biopsy fragmentation in prostate cancer. Int Urol Nephrol. 2010;42(4):965–969.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2015;40:1–52.
   Web of Science ®Google Scholar
• Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006;175(3):820–834.
   PubMed Web of Science ®Google Scholar
• Billis A, Magna LA, Ferreira U. Correlation between tumor extent in radical prostatectomies and preoperative PSA, histological grade, surgical margins, and extraprostatic extension: application of a new practical method for tumor extent evaluation. Int Braz J Urol. 2003;29(2):113–119.
   PubMedGoogle Scholar
• Reis LO, Simão AF, Baracat J, et al. Digital rectal examination standardization for inexperienced hands: teaching medical students. Adv Urol. 2013;2013:1–5.
   Google Scholar
• Fiset PO, Aprikian A, Brimo F. Length of prostate biopsy cores: does it impact cancer detection? Can J Urol. 2013;20(4):6848–6853.
   PubMed Web of Science ®Google Scholar
• Öbek C, Doğanca T, Erdal S, et al. Core length in prostate biopsy: size matters. J Urol. 2012;187(6):2051–2055.
   PubMed Web of Science ®Google Scholar
• Reis LO, Sanches BCF, de Mendonça GB, et al. Gleason underestimation is predicted by prostate biopsy core length. World J Urol. 2015;33(6):821–826.
   PubMed Web of Science ®Google Scholar
• Sanches BCF, Lalli AL, Azal Neto W, et al. Are 10-, 10-12-, or > 12-mm prostate biopsy core quality control cutoffs reasonable? World J Urol. 2018;36(7):1055–1058.
   PubMed Web of Science ®Google Scholar
• Cormio L, Scattoni V, Lorusso F, et al. Prostate cancer detection rates in different biopsy schemes. Which cores for which patients? World J Urol. 2014;32(2):341–346.
   PubMed Web of Science ®Google Scholar
• Durmus T, Goldmann U, Baur AD, et al. MR-guided biopsy of the prostate: comparison of diagnostic specimen quality with 18 G and 16 G biopsy needles. Eur J Radiol. 2013;82(12):e749–e754.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Jalkut M, Dorey F, et al. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000;56(1):87–91.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Amling CL, Dorey F, et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002;60(4):670–674.
   PubMed Web of Science ®Google Scholar
• Lawrentschuk N, Toi A, Lockwood GA, et al. Operator is an independent predictor of detecting prostate cancer at transrectal ultrasound guided prostate biopsy. J Urol. 2009;182(6):2659–2663.
   PubMed Web of Science ®Google Scholar
• Descazeaud A, Rubin MA, Allory Y, et al. What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer? Eur Urol. 2005;48(6):911–915.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Qian J, Drewnowska Drewnowska DK, et al. Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing. Urology. 2010;75(6):1406–1410.
   PubMed Web of Science ®Google Scholar
• Fütterer JJ, Briganti A, De Visschere P, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68(6):1045–1053.
   PubMed Web of Science ®Google Scholar
• Thompson JE, Moses D, Shnier R, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol. 2014;192(1):67–74.
   PubMed Web of Science ®Google Scholar